Christopher Daugherty to Humans
This is a "connection" page, showing publications Christopher Daugherty has written about Humans.
Connection Strength
0.510
-
Anxiety Shapes Expectations of Therapeutic Benefit in Phase I Trials for Patients With Advanced Cancer and Spousal Caregivers. JCO Oncol Pract. 2021 02; 17(2):e101-e110.
Score: 0.021
-
A Qualitative Analysis of Oncology Patient Awareness of Medication Shortages and Their Preferences for How Shortages Should Be Managed. JCO Oncol Pract. 2020 10; 16(10):e1098-e1111.
Score: 0.020
-
A Cross-Sectional Survey of Medical Trainee Experiences During Medication Shortages. J Grad Med Educ. 2020 Feb; 12(1):38-43.
Score: 0.020
-
Mistaking the Trees for the Forest? Oncologist. 2020 04; 25(4):e743.
Score: 0.020
-
Prevalence and Severity of Rationing During Drug Shortages: A National Survey of Health System Pharmacists. JAMA Intern Med. 2019 05 01; 179(5):710-711.
Score: 0.019
-
Reply to J. Schildmann et al. J Clin Oncol. 2019 01 10; 37(2):170-171.
Score: 0.018
-
Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials? J Clin Oncol. 2018 08 20; 36(24):2483-2491.
Score: 0.018
-
Investigator Disclosure and Advanced Cancer Patient Understanding of Informed Consent and Prognosis in Phase I Clinical Trials. J Oncol Pract. 2018 06; 14(6):e357-e367.
Score: 0.018
-
Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. Cancer. 2016 Mar 15; 122(6):954-61.
Score: 0.015
-
User beware: we need more science and less art when measuring financial toxicity in oncology. J Clin Oncol. 2015 Apr 20; 33(12):1414-5.
Score: 0.014
-
The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer. 2014 Oct 15; 120(20):3245-53.
Score: 0.013
-
Oncologists' and physiatrists' attitudes regarding rehabilitation for patients with advanced cancer. PM R. 2012 Feb; 4(2):96-108.
Score: 0.011
-
When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response. Cancer. 2012 Jul 01; 118(13):3417-25.
Score: 0.011
-
Parent opinions regarding the genetic testing of minors for BRCA1/2. J Clin Oncol. 2010 Jul 20; 28(21):3498-505.
Score: 0.010
-
Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: a mailed survey of pediatric oncologists. J Clin Oncol. 2010 Feb 10; 28(5):878-83.
Score: 0.010
-
Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psychooncology. 2009 Feb; 18(2):200-8.
Score: 0.009
-
What are terminally ill cancer patients told about their expected deaths? A study of cancer physicians' self-reports of prognosis disclosure. J Clin Oncol. 2008 Dec 20; 26(36):5988-93.
Score: 0.009
-
An international pilot study of oncology physicians' opinions and practices on Complementary and Alternative Medicine (CAM). Integr Cancer Ther. 2008 Jun; 7(2):70-5.
Score: 0.009
-
Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. Am J Med Genet C Semin Med Genet. 2008 Feb 15; 148C(1):70-7.
Score: 0.009
-
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol. 2008 Mar 10; 26(8):1371-8.
Score: 0.009
-
How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007 Aug 20; 25(24):3705-11.
Score: 0.008
-
Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials. J Clin Oncol. 2007 Aug 10; 25(23):3488-94.
Score: 0.008
-
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol. 2007 Feb 10; 25(5):548-54.
Score: 0.008
-
Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation. J Clin Oncol. 2006 Oct 20; 24(30):4793-5.
Score: 0.008
-
Use of the internet to obtain cancer information among cancer patients at an urban county hospital. J Clin Oncol. 2005 Aug 01; 23(22):4954-62.
Score: 0.007
-
Trusting God and medicine: spirituality in advanced cancer patients volunteering for clinical trials of experimental agents. Psychooncology. 2005 Feb; 14(2):135-46.
Score: 0.007
-
Ethical issues in phase I clinical trials. Clin Adv Hematol Oncol. 2004 Jun; 2(6):358-60.
Score: 0.007
-
Examining ethical dilemmas as obstacles to hospice and palliative care for advanced cancer patients. Cancer Invest. 2004; 22(1):123-31.
Score: 0.006
-
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
Score: 0.006
-
Associations among awareness of prognosis, hopefulness, and coping in patients with advanced cancer participating in phase I clinical trials. Support Care Cancer. 2003 Oct; 11(10):644-51.
Score: 0.006
-
Overcoming obstacles to hospice care: an ethical examination of inertia and inaction. J Clin Oncol. 2003 May 01; 21(9 Suppl):42s-45s.
Score: 0.006
-
'Hitting you over the head': oncologists' disclosure of prognosis to advanced cancer patients. Bioethics. 2003 Apr; 17(2):142-68.
Score: 0.006
-
American oncologists' views of internet use by cancer patients: a mail survey of American Society of Clinical Oncology members. J Clin Oncol. 2003 Mar 01; 21(5):942-7.
Score: 0.006
-
The "cure" for cancer: can the media report the hope without the hype? J Clin Oncol. 2002 Sep 15; 20(18):3761-4.
Score: 0.006
-
Utilization of an Electronic Patient-Reported Outcome Platform to Evaluate the Psychosocial and Quality-of-Life Experience Among a Community Sample of Ovarian Cancer Survivors. JCO Clin Cancer Inform. 2022 08; 6:e2200035.
Score: 0.006
-
Overcoming obstacles to hospice care: an ethical examination of inertia and inaction. J Clin Oncol. 2002 Jun 01; 20(11):2752-5.
Score: 0.006
-
Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organization's Response for Readiness, Mitigation, and Resilience. JCO Oncol Pract. 2021 07; 17(7):365-374.
Score: 0.005
-
Referral and decision making among advanced cancer patients participating in Phase I trials at a single institution. J Clin Ethics. 2001; 12(1):31-8.
Score: 0.005
-
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients. IRB. 2000 May-Jun; 22(3):6-14.
Score: 0.005
-
Multisite, Randomized Trial of Early Integrated Palliative and Oncology Care in Patients with Advanced Lung and Gastrointestinal Cancer: Alliance A221303. J Palliat Med. 2020 07; 23(7):922-929.
Score: 0.005
-
Informed consent, the cancer patient, and phase I clinical trials. Cancer Treat Res. 2000; 102:77-89.
Score: 0.005
-
Before Consent: Qualitative Analysis of Deliberations of Patients With Advanced Cancer About Early-Phase Clinical Trials. JCO Oncol Pract. 2020 01; 16(1):e56-e63.
Score: 0.005
-
Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective. J Clin Oncol. 1999 May; 17(5):1601-17.
Score: 0.005
-
Ethical issues in the development of new agents. Invest New Drugs. 1999; 17(2):145-53.
Score: 0.005
-
Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol. 1998 Jul; 16(7):2305-12.
Score: 0.004
-
Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv. 2018 01 23; 2(2):146-150.
Score: 0.004
-
Learning from our patients: one participant's impact on clinical trial research and informed consent. Ann Intern Med. 1997 Jun 01; 126(11):892-7.
Score: 0.004
-
What advanced cancer patients with limited treatment options know about clinical research: a qualitative study. Support Care Cancer. 2017 10; 25(10):3235-3242.
Score: 0.004
-
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017 02 01; 123(3):476-484.
Score: 0.004
-
Hope and the limits of research. Hastings Cent Rep. 1996 Sep-Oct; 26(5):20; discussion 20-2.
Score: 0.004
-
Interest in initiating an early phase clinical trial: results of a longitudinal study of advanced cancer patients. Psychooncology. 2017 Oct; 26(10):1604-1610.
Score: 0.004
-
An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. J Racial Ethn Health Disparities. 2017 04; 4(2):140-148.
Score: 0.004
-
Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995 May; 13(5):1062-72.
Score: 0.004
-
Pushing the envelope: informed consent in phase I trials. Ann Oncol. 1995 Apr; 6(4):321-3.
Score: 0.004
-
Human subjects protection: an event monitoring committee for research studies of girls from breast cancer families. J Adolesc Health. 2014 Sep; 55(3):352-7.
Score: 0.003
-
General internists' preferences and knowledge about the care of adult survivors of childhood cancer: a cross-sectional survey. Ann Intern Med. 2014 Jan 07; 160(1):11-7.
Score: 0.003
-
Family physician preferences and knowledge gaps regarding the care of adolescent and young adult survivors of childhood cancer. J Cancer Surviv. 2013 Sep; 7(3):275-82.
Score: 0.003
-
Physician preferences and knowledge regarding the care of childhood cancer survivors in Japan: a mailed survey of the Japanese Society of Pediatric Oncology. Jpn J Clin Oncol. 2012 Jun; 42(6):513-21.
Score: 0.003
-
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
Score: 0.003
-
Standards for palliative care delivery in oncology settings. Cancer J. 2010 Sep-Oct; 16(5):436-43.
Score: 0.003
-
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006.
Score: 0.003
-
An intervention to improve cancer patients' understanding of early-phase clinical trials. IRB. 2009 May-Jun; 31(3):1-10.
Score: 0.002
-
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.
Score: 0.002
-
Housestaff and medical student attitudes toward medical errors and adverse events. Jt Comm J Qual Patient Saf. 2007 Aug; 33(8):493-501.
Score: 0.002
-
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64.
Score: 0.002
-
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
Score: 0.002
-
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61.
Score: 0.002
-
Psychosocial adjustment of patients and caregivers prior to allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001 Jun; 27(11):1181-8.
Score: 0.001
-
Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2001 Apr; 41(3-4):297-307.
Score: 0.001
-
A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies. Bone Marrow Transplant. 2000 Apr; 25(8):807-13.
Score: 0.001
-
Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab. 1998 Aug; 83(8):2717-25.
Score: 0.001
-
Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997 Sep; 20(5):369-74.
Score: 0.001
-
Prognostic factors for functional outcome of total knee replacement: a prospective study. J Gerontol A Biol Sci Med Sci. 1996 Jul; 51(4):M152-7.
Score: 0.001
-
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst. 1994 Nov 16; 86(22):1685-93.
Score: 0.001
-
Effect of X-irradiation dose rate on the clonagenic survival of human and experimental animal hematopoietic tumor cell lines: evidence for heterogeneity. Int J Radiat Oncol Biol Phys. 1986 Jan; 12(1):69-73.
Score: 0.000